AUTHORS
Luke R. Smart, MD, Catherine I Segbefia, MBChB2, Enoch Mensah, HND3, Haruna Yakubu, B-Tech4, Susan Stuber, MA5, Priscilla Ekpale, FGC Pharm6, Jonathan Michael Flanagan, Assistant Professor7, Punam Malik, MD8, Tahereh Sara Setayesh, PhD9, Klenam Dzefi-Tettey, MBChB10, Teresa Smith Latham, DrPH11, Russell E E. Ware, MD, PhD12, Yvonne Adomakoh, MD, MBBS13, Theodosia M Kalfa Jr, MD, PhD14
AFFILIATIONS
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
2 Korle Bu Teaching Hospital, Accra, Ghana, University of Ghana Medical School, Accra, Ghana
3 University of Ghana Medical School, Accra, Ghana
4 University of Ghana Medical School, Accra, Ghana
5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
6 University of Ghana Medical School, Accra, Ghana
7 Baylor College of Medicine, Houston, Texas, United States
8 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
9 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
10 University of Health and Allied Sciences, Ho, Ghana
11 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
12 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
13 Korle Bu Teaching Hospital, Accra, Ghana, University of Ghana Medical School, Accra, Ghana
14 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
ABSTRACT
Introduction: HbSC causes significant morbidity and mortality, but hydroxyurea is not currently standard of care and HbF is not recognized as a disease modifier. HbSC erythrocytes display unique characteristics due to cellular dehydration, oxidative stress, HbS polymerization, and HbC crystallization, but the effects of hydroxyurea on these processes are poorly defined.
Methods: Prospective Identification of Variables as Outcomes for Treatment (PIVOT) is a Phase 2, double-blind, placebo-controlled trial of hydroxyurea for Ghanaian children and adults ages 5-50 years with HbSC, designed to identify toxicities and treatment outcomes (PACTR 202108893981080). Rheological parameters from 37 participants receiving hydroxyurea at a stable dose were analyzed in relation to their HbF responses. Ektacytometry assays (LoRRca MaxSis, RR Mechatronics, Zwaag, Netherlands) evaluated erythrocytes under rotational force while subjected to an oxygen (OxygenScan) or osmolar gradient (OsmoScan). Whole blood viscosity was measured with a cone-plate viscometer (AMETEK Brookfield, Middleboro, MA) and crystal violet stain was used to identify RBC inclusions containing denatured hemoglobin. HbF response was analyzed as a continuous and categorical variable as low (<10%), moderate (10-20%), or high HbF (>20%). The relationship between rheological parameters and HbF were examined by Pearson correlation and linear regression analyses. Differences in mean rank values between HbF groups were assessed using Kruskal-Wallis test with adjustment for multiple comparisons. Single nucleotide polymorphisms (SNPs) associated with HbF (BCL11A rs1427407 and rs1186868; HBS1L-MYB rs9399137 and rs28384513; HBG2 rs7482144) were analyzed by PCR for associations with baseline, maximum, and month 24 HbF.
Results: 37 participants (22 children, 15 adults; 19 males, 18 females; age 8.2-51.6 years, mean 25.1) were treated with hydroxyurea for 2.7±0.5 years (mean±SD), on an average dose of 19.9 mg/kg, range 13.4-25.9 mg/kg/day. Treatment HbF values ranged from 3.7 to 47.4%; mean±SD 19.0±11.5%, median 13.9%; 9 individuals had low, 12 moderate, and 16 high HbF responses. Older age correlated with lower baseline HbF (r=-0.20, p=0.0035), but HbF treatment responses were not associated with age, and HbF ≥20% occurred in both children and adults. Both MCV and MCH had a strong (p<0.0001) positive correlation with HbF (r=0.70 and 0.66, respectively), while MCHC had a weak negative correlation (r=-0.25, p=0.135). Improved OsmoScan parameters correlated with higher HbF: Omin (r=0.48, p=0.0028) showing improvement on the surface to volume ratio because of the increased MCV with treatment, EImax (r=0.54, p=0.0005) indicating increased deformability of HbSC erythrocytes, and Ohyp (r=0.64, p<0.0001), reflecting RBC intracellular viscosity. Ohyp also inversely correlated with MCHC (r=-0.62, p<0.0001). OxygenScan showed an increase in EImax (r=0.61, p<0.0001) and EImin (r=0.84, p<0.0001), and a decline in the point-of-sickling (PoS) (r=-0.58, p=0.0002) with higher HbF. EImin values doubled in the high versus low HbF group demonstrating the most significant change observed in RBC rheology parameters. Blood viscosity did not increase with treatment and was negatively correlated with HbF (r=0.33, p=0.0458) at 15 RPM, approximating venous shear stress. RBC inclusions were identified in all participants and declined with higher HbF (r=0.26, p=0.1268). Both BCL11A SNPs were strongly associated with baseline HbF (p<0.001), accounting for ~22-24% of the HbF variance but were not associated with maximum HbF. Neither the HBS1L-MYB nor the HBG2 SNP variants had a significant association with baseline, maximum or month 24 HbF.
Conclusions: Hydroxyurea increases HbF in both children and adults with HbSC and contributes to improved RBC rheology. Higher Ohyp and EImax in Osmoscan reflect improved RBC hydration and superior resilience against shear stress. Increased EImin in OxygenScan indicates improved erythrocyte deformability at hypoxia, expected to be associated with fewer acute vaso-occlusive complications. Lower PoS in OxygenScan reflects improved RBC resistance to sickling at low oxygen tension. These PIVOT trial data provide novel insights into the beneficial mechanisms of hydroxyurea demonstrating improved erythrocyte rheology mediated, at least in part, by increased HbF, support the use of hydroxyurea in HbSC, and highlight the need for further investigation of novel targeted therapies.
DISCLOSURES
Luke R. Smart, MD: No relevant conflicts of interest to declare.